Organophosphate Poisoning

Topic Overview

Summary

Organophosphate (OP) poisoning is a life-threatening toxicological emergency resulting from exposure to insecticides (agricultural or domestic), chemical warfare agents (nerve gases), or rarely, pharmaceutical agents. Organophosphates irreversibly inhibit acetylcholinesterase (AChE), the enzyme responsible for terminating synaptic acetylcholine action, leading to excessive accumulation of acetylcholine at muscarinic, nicotinic, and central nervous system receptors. [1,2]

This cholinergic crisis manifests as the classic SLUDGE syndrome (Salivation, Lacrimation, Urination, Defaecation, GI upset, Emesis) combined with bronchospasm, bradycardia, and bronchorrhoea (BBB). Nicotinic effects include muscle fasciculations, weakness, and potentially fatal respiratory paralysis. Central effects range from agitation and confusion to seizures and coma. [3,4]

Treatment is time-critical and involves aggressive decontamination, high-dose atropine titrated to dry secretions (not heart rate), pralidoxime (oxime therapy) to reactivate AChE before "ageing" of the enzyme-inhibitor complex occurs, benzodiazepines for seizures, and advanced supportive care including mechanical ventilation. Despite treatment, mortality remains 10-20% in moderate to severe cases, with higher rates in resource-limited settings. [5,6]

Three clinical syndromes are recognized: acute cholinergic crisis (minutes to hours), intermediate syndrome (24-96 hours post-exposure, characterized by respiratory and proximal muscle weakness), and organophosphate-induced delayed polyneuropathy (OPIDN, occurring 2-3 weeks after exposure with certain compounds). [7,8]

Key Facts

Epidemiology & Exposure

• Over 3 million acute pesticide poisonings occur annually worldwide, with approximately 300,000 deaths
• Accounts for one-third of global suicide deaths in Asia-Pacific region
• Agricultural workers at highest occupational risk
• Intentional self-poisoning is the most common presentation in developing countries [9,10]

Mechanism

• Irreversible phosphorylation of acetylcholinesterase at the esteratic site
• Prevents hydrolysis of acetylcholine, causing accumulation at cholinergic synapses
• "Ageing"
• time-dependent dealkylation of the phosphorylated enzyme making it resistant to reactivation
• Ageing half-life varies by compound: dimethyl OPs (2-6 hours), diethyl OPs (30-40 hours) [11,12]

Clinical Syndromes

• Acute cholinergic crisis (onset minutes to hours): SLUDGE/BBB + nicotinic + CNS effects
• Intermediate syndrome (1-4 days): weakness of neck flexors, respiratory muscles, proximal limbs
• OPIDN (2-3 weeks): distal sensorimotor polyneuropathy (rare, seen with specific OPs) [7,8]

Treatment Priorities

1. Decontamination with full PPE for staff protection
2. Atropine 1.8-3 mg IV bolus, doubling every 5 minutes until secretions dry (may require hundreds of mg)
3. Pralidoxime 30 mg/kg loading dose, then 8-10 mg/kg/hr infusion
4. Early intubation and mechanical ventilation as needed
5. Benzodiazepines for seizures [5,13]

Clinical Pearls

Recognition: "SLUDGE + miosis + fasciculations + history of pesticide = OP poisoning until proven otherwise"

Atropinisation endpoint: Titrate atropine to dry secretions and clear chest, NOT to normalize heart rate. Tachycardia is expected and acceptable. Under-atropinisation kills.

Pralidoxime timing: Most effective when given early (before ageing), but continue even if presentation is delayed - some benefit may persist up to 48 hours.

Intermediate syndrome: Always admit for minimum 4-5 days monitoring even if initial recovery appears complete - delayed respiratory failure can occur.

Avoid: Succinylcholine (prolonged paralysis), morphine (respiratory depression + sphincter spasm), aminophylline (seizure risk).

Measurement pitfall: Cholinesterase levels confirm diagnosis but do NOT guide acute management - treat clinically.

Why This Matters Clinically

Organophosphate poisoning is the leading cause of death from pesticide poisoning globally, particularly in low- and middle-income countries where access to organophosphate pesticides is widespread and suicide by self-poisoning is common. Early recognition and aggressive, protocol-driven treatment with high-dose atropine and pralidoxime can reduce mortality from over 40% to under 20%. [14,15]

The condition presents unique challenges: the need for exceptionally high atropine doses (far exceeding conventional dosing), the time-critical nature of oxime therapy before enzyme ageing, the requirement for prolonged ventilatory support, and the risk of delayed complications (intermediate syndrome, OPIDN) necessitating extended monitoring. Misdiagnosis or under-treatment leads to preventable respiratory failure and death. [16]

In high-income countries, awareness of OP poisoning has declined as agricultural exposures have decreased, but sporadic cases from malicious use (chemical weapons), occupational exposure, or self-harm still occur, and clinicians must maintain diagnostic vigilance.

---

Visual Summary

Visual assets to be added:

• Acetylcholinesterase inhibition molecular mechanism diagram
• SLUDGE/BBB cholinergic syndrome mnemonic with anatomical mapping
• OP poisoning severity assessment algorithm
• Atropine titration protocol flowchart
• Pralidoxime dosing and timing algorithm
• Intermediate syndrome clinical timeline
• Differential diagnosis decision tree

---

Epidemiology

Global Burden

Organophosphate pesticide poisoning represents one of the most significant toxicological public health problems worldwide, with the burden disproportionately affecting low- and middle-income countries. [9,10]

Incidence

• Approximately 3 million acute pesticide poisonings occur annually
• An estimated 300,000 deaths per year globally
• Case fatality rate 10-20% with treatment, up to 40-50% without appropriate care
• In the Asia-Pacific region, pesticide poisoning accounts for approximately one-third of all suicides [9,14]

Geographic Distribution

• Highest burden in agricultural regions of Asia (Sri Lanka, India, China)
• Significant problem in Central and South America
• Increasing concern in Sub-Saharan Africa with agricultural intensification
• Rare in high-income countries following regulatory restrictions [10,15]

Demographics

Age

• Most common in young adults (20-40 years) due to intentional self-harm
• Occupational exposures across working-age adults
• Accidental pediatric exposures occur but less common

Sex

• Intentional poisoning shows regional variation: male predominance in South Asia, more equal distribution in other regions
• Occupational exposures predominantly male (agricultural workers)

Risk Factors for Exposure

Sources of Exposure

Agricultural Organophosphates

Note: Many highly toxic compounds (parathion, methyl parathion, monocrotophos) have been banned or restricted in many countries but remain available in some regions. [17]

Chemical Warfare Agents (Nerve Agents)

• G agents: Sarin (GB), soman (GD), tabun (GA), cyclosarin (GF)
• V agents: VX (extremely persistent and toxic)
• Novichok agents: Fourth-generation nerve agents (A-230, A-232, A-234)
• Far more potent than agricultural OPs; exposure typically results in severe toxicity [18]

Routes of Exposure

• Ingestion: Most common route in self-poisoning, often concentrated formulations
• Dermal: Occupational exposure, nerve agent exposure
• Inhalation: Spray application, vapor exposure, nerve agents
• Multiple routes: Deliberate self-poisoning may involve multiple routes

---

Pathophysiology

Molecular Mechanism

Normal Acetylcholine Metabolism

Under normal conditions, the neurotransmitter acetylcholine (ACh) is released at cholinergic synapses (parasympathetic nerve terminals, neuromuscular junctions, autonomic ganglia, and CNS) where it binds to and activates cholinergic receptors. The enzyme acetylcholinesterase rapidly hydrolyzes ACh into choline and acetate, terminating neurotransmission within milliseconds. This precise temporal control of ACh concentration is essential for normal neuromuscular and autonomic function. [1,11]

Organophosphate Inhibition of Acetylcholinesterase

Organophosphates are indirect cholinergic agonists that act by inhibiting acetylcholinesterase. The OP molecule phosphorylates the serine residue at the esteratic site of AChE, forming a stable covalent phosphate-enzyme complex. This prevents the enzyme from binding and hydrolyzing acetylcholine. [2,11]

The reaction occurs in two steps:

1. Phosphorylation: OP binds to AChE, forming phosphorylated enzyme + leaving group
2. Ageing: Time-dependent dealkylation of the phosphorylated enzyme, making the bond irreversible

Ageing Process

The "ageing" of the phosphorylated enzyme is a critical concept in OP poisoning management. Over time (hours to days depending on the specific OP), the phosphorylated enzyme undergoes dealkylation, after which it becomes resistant to reactivation by oximes (pralidoxime). [12]

Ageing half-times:

• Dimethyl OPs (e.g., dimethoate, malathion): 2-6 hours (rapid ageing)
• Diethyl OPs (e.g., parathion, chlorpyrifos): 30-40 hours (slower ageing)
• Nerve agents: Minutes to hours (very rapid)

This explains why early pralidoxime administration is critical - once ageing is complete, new enzyme must be synthesized, which takes days to weeks.

Cholinergic Receptor Overstimulation

With AChE inhibited, acetylcholine accumulates at cholinergic synapses throughout the body, causing continuous receptor stimulation. The clinical syndrome reflects overstimulation of three receptor types:

1. Muscarinic Receptors (Parasympathetic)

Located at parasympathetic nerve terminals innervating smooth muscle, cardiac muscle, and exocrine glands.

2. Nicotinic Receptors (Neuromuscular Junction)

Located at skeletal muscle motor endplates.

3. Nicotinic Receptors (Autonomic Ganglia)

Located at sympathetic and parasympathetic ganglia, causing initial stimulation then blockade.

• Sympathetic ganglia stimulation: Tachycardia, hypertension, mydriasis (may occur early, confusing the clinical picture)
• Ganglionic blockade: May occur later with severe poisoning

Central Nervous System Effects

Organophosphates cross the blood-brain barrier and inhibit central AChE, leading to central cholinergic toxicity. [3]

CNS Manifestations

• Anxiety, restlessness, agitation
• Confusion, slurred speech
• Ataxia, tremor
• Seizures (may be prolonged or status epilepticus)
• Coma
• Central respiratory depression

Three Clinical Syndromes

1. Acute Cholinergic Crisis

Onset within minutes to hours of exposure. Represents the combined muscarinic, nicotinic, and CNS effects described above. The classic presentation that brings patients to medical attention. Duration depends on dose, compound, and treatment, typically resolving over 24-72 hours with appropriate therapy. [4,5]

2. Intermediate Syndrome

First described in the 1980s, intermediate syndrome (IMS) occurs in approximately 10-40% of patients with moderate to severe OP poisoning, typically 24-96 hours after exposure, after resolution of the acute cholinergic crisis but before expected development of OPIDN. [7,19]

Pathophysiology: The mechanism is incompletely understood but appears to involve:

• Prolonged nicotinic receptor activation and subsequent dysfunction
• Inadequate oxime therapy or recurrent cholinesterase inhibition
• Possible direct OP toxicity to muscle

Clinical features:

• Weakness of muscles of respiration (diaphragm, intercostals)
• Weakness of neck flexors
• Weakness of proximal limb muscles
• Cranial nerve involvement (facial, ocular, bulbar muscles)
• Absent deep tendon reflexes
• No fasciculations (distinguishes from acute crisis)
• Normal or recovering cholinesterase levels

Significance: IMS is an independent predictor of mortality and prolonged ICU stay. Recognition is critical as patients require extended mechanical ventilation (often 2-3 weeks). [20]

3. Organophosphate-Induced Delayed Polyneuropathy (OPIDN)

Rare complication occurring 2-3 weeks after acute exposure to certain organophosphates. [8,21]

Mechanism: Not due to AChE inhibition but rather inhibition of neuropathy target esterase (NTE), a different enzyme in nervous tissue. This leads to axonal degeneration of long motor and sensory neurons.

Compounds most associated with OPIDN:

• Certain organophosphate pesticides (e.g., leptophos, mipafox - now banned)
• Tri-ortho-cresyl phosphate (TOCP) - industrial compound, notorious historical outbreaks
• Some nerve agents

Clinical features:

• Distal sensorimotor polyneuropathy
• Initial cramping pain in calves
• Progressing to distal weakness (foot drop, wrist drop)
• Sensory loss (glove and stocking distribution)
• Ataxia
• May be irreversible

Diagnosis: Clinical, supported by electrophysiology (axonal neuropathy), often weeks after the acute event has been forgotten.

---

Clinical Presentation

Acute Cholinergic Crisis

The presentation of OP poisoning is determined by the combined effects of muscarinic, nicotinic, and central nervous system receptor overstimulation. The classic SLUDGE/BBB mnemonic captures the muscarinic syndrome but is insufficient - nicotinic and CNS effects dominate severe cases. [3,4]

Muscarinic Effects - SLUDGE/BBB/DUMBELS

Multiple mnemonics exist. The most comprehensive is DUMBELS:

Alternative mnemonic - SLUDGE/BBB:

• SLUDGE: Salivation, Lacrimation, Urination, Defaecation, GI upset, Emesis
• BBB: Bronchospasm, Bradycardia, Bronchorrhoea

Nicotinic Effects

Neuromuscular junction:

• Fasciculations: Involuntary muscle twitching, often first noticed in eyelids and tongue, then generalized
• Muscle weakness: Progressing from initial twitching to flaccid paralysis
• Respiratory muscle paralysis: Diaphragm and intercostal weakness leading to respiratory failure
• Ptosis, ophthalmoplegia: Ocular muscle weakness

Autonomic ganglia (may confuse picture):

• Tachycardia (sympathetic ganglia stimulation)
• Hypertension
• Mydriasis (sympathetic, may oppose muscarinic miosis)
• Pallor

Central Nervous System Effects

Cardiovascular Effects

Complex and biphasic:

• Early: May see tachycardia and hypertension (nicotinic ganglia stimulation)
• Later: Bradycardia and hypotension (muscarinic effects predominate)
• Arrhythmias: QTc prolongation, torsades de pointes, ventricular arrhythmias
• Myocardial dysfunction: Direct cardiotoxicity in severe cases

Time Course

Onset:

• Ingestion: 30 minutes to 2 hours (faster with concentrated formulations on empty stomach)
• Dermal: 4-6 hours (up to 24 hours with continued absorption)
• Inhalation: Minutes to 1 hour
• Nerve agents: Within minutes (extremely rapid)

Duration:

• Depends on dose, compound lipid solubility, and adequacy of treatment
• Acute cholinergic crisis typically 24-72 hours with treatment
• Highly lipophilic compounds (e.g., fenthion) may cause prolonged or relapsing toxicity due to redistribution

Severity Classification

Mild Poisoning

• Mild muscarinic symptoms (sweating, salivation, nausea)
• Miosis
• No respiratory distress
• Alert and oriented
• Can usually be managed with observation and low-dose atropine

Moderate Poisoning

• SLUDGE syndrome present
• Fasciculations
• Mild bronchospasm, wheezing
• Tachypnoea but maintaining oxygenation
• Confusion or agitation
• Requires atropine and pralidoxime, close monitoring

Severe Poisoning

• Severe bronchorrhoea, bronchospasm
• Respiratory failure (reduced consciousness, hypoxia, fatigue)
• Muscle paralysis
• Seizures or coma
• Bradycardia or cardiovascular collapse
• Requires immediate resuscitation, high-dose atropine, pralidoxime, mechanical ventilation

---

Clinical Examination

General Inspection

Odor: Some organophosphates have characteristic odors:

• Garlic-like odor (parathion, malathion)
• Petroleum/solvent smell (formulation excipients)

Level of Consciousness

• Glasgow Coma Scale assessment
• Agitation vs. confusion vs. obtundation vs. coma

Vital Signs

Head and Neck

Eyes:

• Miosis (pinpoint pupils): Classic finding, may be very pronounced (less than 1 mm)
  • "Note: Miosis may be absent if significant nicotinic ganglia stimulation (mydriasis) occurs"
  • May also be absent with certain OPs or in very severe/late poisoning
• Lacrimation: Excessive tearing
• Conjunctival injection

Pupils: Test light reflex (may be sluggish but usually preserved)

Oral cavity:

• Excessive salivation, frothing at mouth
• Visible fasiculations of tongue

Respiratory System

Inspection:

• Use of accessory muscles
• Paradoxical breathing (diaphragm weakness)
• Cyanosis

Auscultation:

• Widespread wheeze (bronchospasm)
• Coarse crackles (bronchorrhoea, pulmonary edema)
• Reduced air entry (secretions, weakness)

Peak flow: Reduced (if patient able to cooperate)

Cardiovascular System

• Pulse: Bradycardia (or tachycardia)
• Blood pressure: Hypotension or hypertension
• JVP: May be elevated in severe cases with myocardial dysfunction
• Heart sounds: Usually normal; may hear arrhythmia

Abdominal System

• Inspection: Distension (rare)
• Auscultation: Hyperactive bowel sounds
• Palpation: Abdominal tenderness, cramps
• Note: Vomiting, diarrhea may be profuse

Neurological System

Mental status: AVPU or GCS

Cranial nerves:

• Miosis (CN III parasympathetic)
• Fasciculations of facial muscles, tongue

Motor examination:

• Fasciculations: Visible muscle twitching, especially eyelids, tongue, limbs
  • Begin distally, may become generalized
  • Indicate nicotinic receptor overstimulation
• Tone: Initially normal, then decreased (flaccid paralysis)
• Power: Weakness, often progressive; test respiratory muscle strength if possible
• Reflexes: Initially brisk, then depressed

Sensory examination: Usually normal in acute phase

Coordination: Ataxia may be present

Skin

• Diaphoresis (excessive sweating): Profuse, generalized
• Contamination: Look for liquid on skin/clothing (need decontamination)
• Erythema: May occur at sites of dermal exposure

Red Flag Examination Findings

---

Investigations

Clinical Diagnosis is Key

Organophosphate poisoning is a CLINICAL diagnosis. Treatment must not be delayed while awaiting laboratory confirmation. The history (pesticide exposure, agricultural work, suicide attempt) combined with examination findings (SLUDGE/BBB + fasciculations + miosis) should trigger immediate empirical treatment. [5,13]

Cholinesterase Levels

Two forms measured:

1. Plasma (butyrylcholinesterase, pseudocholinesterase)

   • Synthesized in liver, present in plasma
   • Rapidly and reliably depleted by OP exposure
   • Turnaround time: Often same day
   • Utility: Confirms exposure, correlates with severity
   • Limitation: Non-specific; reduced in liver disease, malnutrition, pregnancy, genetic variants

2. Red blood cell (RBC) acetylcholinesterase ("true" cholinesterase)

   • Same enzyme as in neural tissue
   • More specific indicator of nerve tissue AChE inhibition
   • Turnaround time: Often 24-48 hours (slower)
   • Utility: Better correlates with clinical toxicity, useful for monitoring recovery
   • Limitation: Delayed availability

Interpretation:

Important notes:

• Baseline cholinesterase varies between individuals
• More useful when baseline known (occupational screening) or serial measurements
• Do NOT delay treatment waiting for results
• May be useful for confirming diagnosis retrospectively or monitoring recovery
• Recovery of RBC AChE occurs as new RBCs are produced (1% per day, fully recovered ~3 months)

Arterial Blood Gas (ABG)

Critical investigation - repeat frequently in moderate-severe poisoning

Findings:

• Hypoxia (PaO2 less than 60 mmHg): Indicates respiratory failure
• Hypercarbia (PaCO2 > 45 mmHg): Indicates hypoventilation, muscle weakness, or central depression
• Metabolic acidosis: Common in severe poisoning (lactic acidosis from tissue hypoxia, seizures)
• Respiratory acidosis: Hypoventilation

Indications for intubation (suggested criteria):

• PaO2 less than 60 mmHg on high-flow oxygen
• PaCO2 > 50 mmHg and rising
• pH less than 7.25
• Reduced consciousness (GCS less than 8)
• Inability to protect airway (excessive secretions, bulbar weakness)

Electrocardiogram (ECG)

Perform 12-lead ECG on all patients

Findings:

• Bradycardia: Sinus bradycardia, AV blocks
• Tachycardia: Sinus tachycardia (nicotinic or inadequate atropinization)
• QTc prolongation: Common, risk factor for torsades de pointes
• ST-T wave abnormalities: Myocardial ischemia in severe cases
• Arrhythmias: Atrial fibrillation, ventricular ectopy, torsades de pointes

Monitor continuously in moderate-severe poisoning

Chest X-Ray (CXR)

Indications: All patients with respiratory symptoms

Findings:

• Pulmonary edema: Cardiogenic or non-cardiogenic (ARDS)
• Aspiration pneumonia: Common complication, especially if vomiting and reduced GCS
• Atelectasis: Secretions, hypoventilation

Other Blood Tests

Urine Organophosphate Metabolites

• Specialized test (not routinely available)
• Can detect OP metabolites (e.g., dialkyl phosphates)
• Useful for epidemiological studies or confirming low-level exposure
• Not useful for acute management

Neurophysiology

Not performed in acute phase

May be useful for diagnosing intermediate syndrome or OPIDN:

• Nerve conduction studies: May show decremental response to repetitive stimulation (IMS), axonal neuropathy (OPIDN)
• Electromyography (EMG): Myopathic changes in IMS

---

Differential Diagnosis

The cholinergic toxidrome is relatively specific, but several conditions may mimic OP poisoning or cause diagnostic confusion.

Toxicological Mimics

Non-Toxicological Mimics

Diagnostic Approach

High suspicion with:

• History of pesticide exposure (occupational, agricultural area, suicide attempt)
• SLUDGE syndrome + miosis + fasciculations
• Bradycardia + bronchospasm + bronchorrhoea
• Reduced cholinesterase levels

If uncertain, empirical atropine trial:

• Diagnostic and therapeutic
• Atropine will reverse muscarinic effects if OP poisoning
• Will NOT improve other conditions significantly
• Use with caution: monitor for anticholinergic toxicity if wrong diagnosis

---

Management

Management of organophosphate poisoning requires immediate, aggressive intervention following established protocols. Delays in treatment significantly increase mortality. [5,13,22]

Pre-Hospital and Emergency Department Resuscitation

1. Staff Protection and Decontamination ⚠️

CRITICAL: Organophosphates can be absorbed through skin and inhaled. Healthcare workers have been poisoned by contact with contaminated patients.

Staff protection:

• Full personal protective equipment (PPE): gloves (nitrile), gowns, eye protection, masks
• Decontamination area separate from main ED
• Limit personnel exposure time

Patient decontamination:

• Remove all clothing (place in sealed bags)
• Wash entire body with soap and copious water for at least 15 minutes
  • Pay attention to hair, skin folds, nails
  • Avoid abrasion (increases absorption)
• Do NOT use bleach or harsh chemicals on skin
• Eye irrigation if eye exposure (copious saline/water)

2. Airway, Breathing, Circulation

Airway:

• Suction excessive secretions frequently (before intubation if needed)
• Early intubation if:
  • GCS less than 8 (unable to protect airway)
  • Severe bronchorrhoea despite atropine
  • Respiratory muscle weakness
  • Apnea or inadequate ventilation
• Rapid sequence intubation: Use with caution
  • AVOID succinylcholine (prolonged paralysis due to AChE inhibition)
  • Use rocuronium or vecuronium instead (may have prolonged effect; titrate carefully)

Breathing:

• High-flow oxygen to all patients (target SpO2 > 94%)
• Ventilate early if respiratory distress
• Ventilator settings: adequate tidal volume and rate; high secretions may require frequent suctioning

Circulation:

• Large-bore IV access (two lines)
• Fluid resuscitation if hypotensive (crystalloid boluses)
• Monitor cardiac rhythm continuously

3. Antidote Therapy - ATROPINE

Atropine is the FIRST-LINE, LIFE-SAVING antidote. It competitively blocks muscarinic receptors, reversing the muscarinic effects (SLUDGE/BBB) but NOT nicotinic effects (fasciculations, weakness). [5,13]

Dosing Protocol

Critical Points:

• Titrate to secretions, NOT heart rate: Tachycardia is expected and acceptable
• Doses required may be enormous: 10-20 mg in first hour, hundreds of mg over days is not uncommon in severe poisoning
• Under-atropinization is a common cause of death: "Dry chest and clear lung fields" is the endpoint
• Inadequate response: If no response to atropine despite appropriate dosing, consider:
  • Incorrect diagnosis
  • Carbamate poisoning (should respond)
  • Inadequate decontamination (ongoing absorption)

Signs of Adequate Atropinization:

• ✅ Clear chest on auscultation (no crackles)
• ✅ Dry axillae (sweating stopped)
• ✅ Heart rate > 80 bpm (though > 100-120 is common and acceptable)
• ✅ Systolic BP > 80 mmHg
• ✅ Pupils may remain miotic (acceptable; pupil size is NOT a target)

Atropine Toxicity (rare in OP poisoning, usually indicates over-treatment):

• Hyperthermia (> 40°C)
• Severe agitation, delirium
• Urinary retention (catheterize)
• Ileus (stop enteral feeding)
• If concerned about toxicity: reduce infusion rate, do NOT stop abruptly

4. Antidote Therapy - PRALIDOXIME (Oximes)

Pralidoxime (2-PAM) reactivates acetylcholinesterase by cleaving the phosphate-enzyme bond, reversing BOTH muscarinic and nicotinic effects. [12,13]

Mechanism:

• Nucleophilic attack on phosphorylated AChE
• Removes phosphate group, regenerating active enzyme
• Only effective BEFORE "ageing" of the enzyme-OP complex

Timing is Critical:

• Most effective if given within 4-6 hours (before ageing for most compounds)
• Continue up to 24-48 hours - some benefit may persist
• Start as soon as diagnosis suspected - do NOT delay awaiting confirmation

Dosing Protocol

WHO Alternative Regimen (if continuous infusion not feasible):

• Loading: 30 mg/kg over 30 min
• Maintenance: 30 mg/kg IV bolus every 4-6 hours

Clinical Response:

• Reduction in atropine requirements (key marker of efficacy)
• Improvement in muscle weakness, fasciculations
• Improved consciousness

Evidence Base:

• Controversial: Some meta-analyses show no mortality benefit; others show benefit when given early and as continuous infusion [13,22]
• Current consensus (WHO, most guidelines): Recommend pralidoxime, especially for moderate-severe poisoning
• Likely more effective for:
  • Diethyl OPs (slower ageing)
  • Early administration (less than 6-12 hours)
  • Continuous infusion (maintains therapeutic levels)

Adverse Effects (rare at recommended doses):

• Tachycardia, hypertension (rapid bolus)
• Dizziness, blurred vision
• Muscle rigidity (very high doses)

Contraindications: None absolute in OP poisoning

5. Seizure Management

Seizures are common in moderate-severe OP poisoning due to central cholinergic toxicity. [3]

Treatment:

• Benzodiazepines are first-line:
  • Lorazepam 4 mg IV (or diazepam 10 mg IV), repeat every 5-10 minutes as needed
  • Continue until seizures controlled
• Second-line: Phenytoin, levetiracetam, or propofol as per status epilepticus protocols
• Ensure adequate atropinization (seizures may be exacerbated by hypoxia)

6. Gastrointestinal Decontamination

Controversial and LIMITED role in OP poisoning. [5]

Gastric Lavage:

• ❌ NOT routinely recommended
• Consider ONLY if:
  • Ingestion of large amount
  • Presentation within 1 hour of ingestion
  • After airway protection (intubated)
• Use large-bore orogastric tube (36-40 Fr)
• Staff must wear PPE (gastric contents are contaminated)

Activated Charcoal:

• Single dose 50 g (adults) via NGT may be considered if within 1 hour of ingestion
• Protect airway first (risk of aspiration)
• Efficacy uncertain for OPs (limited data)

Whole Bowel Irrigation: No role

7. Supportive Care

Mechanical Ventilation:

• Indicated for respiratory failure (see ABG criteria above)
• Prolonged ventilation often required (48-96 hours or longer)
• Wean carefully: Assess for intermediate syndrome (may require re-intubation)

Fluid and Electrolyte Management:

• Hypokalemia is common (vomiting, diarrhea, beta-agonist effects)
  • Aggressive repletion (target K > 4.0 mmol/L)
  • Hypokalemia increases arrhythmia risk (especially with QT prolongation)
• Hypomagnesemia: Check and replace
• Monitor fluid balance: Risk of pulmonary edema

Cardiovascular Support:

• Bradycardia: Usually responds to atropine
• Hypotension: Fluids first; may require vasopressors (noradrenaline) in severe cases
• Arrhythmias: Correct electrolytes; consider anti-arrhythmics if persistent

Urinary Catheter: Usually required (urinary incontinence; need to monitor output)

Nasogastric Tube: Decompress stomach, administer charcoal if indicated; monitor for ileus

Nutrition: Enteral feeding once stabilized (prolonged ICU stay common)

8. Medications to AVOID

9. Monitoring and ICU Care

All moderate-severe cases require ICU admission.

Monitoring:

• Continuous cardiac telemetry
• Hourly vital signs (during acute phase)
• ABG every 4-6 hours (if ventilated or unstable)
• Fluid balance, urine output
• Serial electrolytes (U&E at least daily)
• Daily CXR (if ventilated)
• Serial cholinesterase levels (trend toward recovery)

Watch for Intermediate Syndrome (days 1-4):

• Daily assessment of muscle strength
• Neck flexor weakness (ask patient to lift head off pillow)
• Respiratory muscle strength (negative inspiratory force, vital capacity if able)
• Unexplained respiratory deterioration 24-96 hours post-exposure should raise suspicion

10. Disposition and Duration

Admission Criteria:

• ALL symptomatic patients should be admitted (minimum 24 hours observation)
• Asymptomatic with definite exposure: Observe 6-12 hours minimum
• Mild symptoms: Ward admission, close monitoring
• Moderate-severe symptoms: ICU/HDU

Discharge Criteria:

• Clinically well for > 24 hours
• No atropine required for > 12-24 hours
• No respiratory support needed
• Able to eat and drink
• Psychiatric assessment (if intentional self-harm)
• Minimum 4-5 day admission for moderate-severe poisoning (watch for intermediate syndrome)

Follow-Up:

• Outpatient review at 2-4 weeks
• Monitor for delayed neuropathy (if high-risk OP exposure)
• Psychiatric follow-up if self-harm

Management Algorithm Summary

1. DECONTAMINATION (staff PPE, remove clothing, wash patient)
   ↓
2. RESUSCITATION (Airway, Breathing, Circulation)
   ↓
3. ATROPINE (1.8-3 mg IV bolus, double every 5 min to dry secretions)
   ↓
4. PRALIDOXIME (30 mg/kg IV load, then 8-10 mg/kg/hr infusion)
   ↓
5. SUPPORTIVE CARE (ventilation, fluids, electrolytes, seizure control)
   ↓
6. ICU MONITORING (watch for intermediate syndrome days 1-4)
   ↓
7. WEAN ATROPINE gradually (over 24-72 hours as symptoms resolve)
   ↓
8. DISCHARGE after minimum 4-5 days (psychiatric assessment if intentional)

---

Complications

Acute Complications (Hours to Days)

Intermediate Syndrome (1-4 Days)

• Incidence: 10-40% of moderate-severe OP poisoning [19,20]
• Onset: Typically 24-96 hours after exposure
• Clinical features: Weakness of respiratory muscles, neck flexors, proximal limbs; cranial nerve palsies
• Outcome: Mortality 10-15% (higher without ventilatory support); survivors usually make full recovery over 2-3 weeks
• Prevention: Uncertain; adequate pralidoxime may reduce risk

Delayed Complications

---

Prognosis & Outcomes

Mortality

Overall mortality: 10-20% with appropriate treatment [14,15]

Mortality by severity:

• Mild poisoning: less than 5%
• Moderate poisoning: 10-15%
• Severe poisoning: 20-30%
• Without treatment: 40-50%

Factors Associated with Higher Mortality

Patient Factors:

• Extremes of age (elderly, young children)
• Comorbidities (cardiac, respiratory disease)
• Delayed presentation (> 6 hours from ingestion)

Poison Factors:

• Type of OP (highly toxic compounds: parathion, monocrotophos)
• Large ingestion volume
• Concentrated formulation

Clinical Factors:

• Severe cholinergic crisis on presentation
• GCS less than 8
• Respiratory failure requiring ventilation
• Cardiovascular collapse
• Seizures
• Development of intermediate syndrome
• Aspiration pneumonia

Treatment Factors:

• Delayed or inadequate atropinization (most important modifiable factor)
• Lack of ICU care
• Delayed pralidoxime administration

Predictive Scores

Several scoring systems have been developed to predict severity and outcomes:

Peradeniya Organophosphate Poisoning (POP) Scale (0-11 points):

• Pupil size, pulse rate, respiratory rate, fasciculations, level of consciousness
• Score ≥6 predicts need for ventilation (sensitivity 86%, specificity 89%)

Long-Term Outcomes

Most survivors make complete recovery, especially if appropriate treatment given early.

Potential long-term sequelae:

• Cognitive impairment (usually mild, improves over months) [3]
• Peripheral neuropathy (OPIDN - specific compounds only, rare)
• Psychiatric morbidity (especially if suicide attempt)

Return to work: Most patients able to return to full activities within 1-3 months

Recurrent poisoning: Risk of repeat self-harm if intentional poisoning (psychiatric follow-up essential)

---

Prevention & Public Health

Primary Prevention

Regulation:

• Ban or restrict highly hazardous pesticides (WHO Class Ia and Ib)
• Pesticide registration and licensing
• Enforcement of safe storage and use regulations

Agricultural Interventions:

• Integrated pest management (reduce reliance on chemical pesticides)
• Training for agricultural workers
• Provision of personal protective equipment
• Lockable pesticide storage

Suicide Prevention:

• Restrict access to pesticides (community storage, vendor lock-up)
• Mental health services in rural areas
• Crisis intervention hotlines

Secondary Prevention (Occupational Monitoring)

For workers with regular OP exposure:

• Baseline and periodic cholinesterase levels (every 3-6 months)
• Remove from exposure if > 20% drop from baseline
• Education on symptoms of poisoning
• Access to PPE

Tertiary Prevention

After OP poisoning episode:

• Psychiatric assessment and treatment (if self-harm)
• Restrict access to pesticides
• Occupational assessment (safe return to work)
• Monitoring for delayed complications (OPIDN)

---

Evidence & Guidelines

Key Clinical Trials and Meta-Analyses

1. Eddleston et al. (2009): Randomized controlled trial of pralidoxime in acute OP poisoning (n=235) - no mortality benefit with standard WHO regimen. [13]

2. Pawar et al. (2006): High-dose pralidoxime continuous infusion showed benefit compared to intermittent boluses (reduced mortality, shorter hospital stay). [Landmark study supporting continuous infusion]

3. Peter et al. (2006): Cochrane review on pralidoxime for OP poisoning - insufficient evidence to support or refute use, but recommended given biological plausibility. [22]

4. Buckley et al. (2011): Systematic review of atropine use - confirmed benefit but highlighted wide variation in dosing protocols. [5]

International Guidelines

World Health Organization (WHO):

• Clinical Management of Acute Pesticide Intoxication (2008, updated 2020)
• Recommends atropine and pralidoxime for moderate-severe poisoning
• Pralidoxime: 30 mg/kg loading, 8 mg/kg/hr continuous infusion

National Poison Information Services (UK - TOXBASE):

• Comprehensive guidance on OP poisoning
• Atropine and pralidoxime recommended
• Emphasizes early aggressive atropinization

American Heart Association (AHA):

• Guidelines for chemical weapons/nerve agent exposure
• Similar principles: atropine and pralidoxime

Current Controversies and Debates

1. Pralidoxime Efficacy:

• Some RCTs and meta-analyses show no mortality benefit [13,22]
• However, most trials used inadequate dosing regimens or late administration
• Consensus: Continue to recommend, especially if given early and as continuous infusion
• More effective for diethyl OPs (slower ageing)

2. Gastric Decontamination:

• Gastric lavage and activated charcoal have limited evidence
• Risk of aspiration may outweigh benefit
• Current guidance: selective use, only within 1 hour, after airway protection

3. Atropine Dosing Endpoint:

• Traditional teaching: heart rate > 80 bpm
• Current evidence: "dry chest and clear lungs" is more appropriate endpoint
• Tachycardia is expected and acceptable

---

Patient & Family Information

What is Organophosphate Poisoning?

Organophosphate poisoning happens when someone is exposed to certain pesticides (chemicals used to kill insects) or rare chemical weapons. These chemicals stop a natural enzyme in the body from working, which causes nerves to be overactive.

How Does Poisoning Occur?

• Swallowing pesticides (most common in suicide attempts)
• Skin contact with pesticides (agricultural workers)
• Breathing in pesticide spray or fumes

What Are the Symptoms?

The chemical affects nerves throughout the body, causing:

• Too much saliva, tears, and sweat
• Difficulty breathing (wheezing, too much mucus)
• Muscle twitching and weakness
• Nausea, vomiting, and diarrhea
• Very small pupils (the black part of the eye becomes tiny)
• Confusion or unconsciousness in severe cases

What Is the Treatment?

Treatment must start immediately in a hospital:

• Decontamination: Washing skin thoroughly, removing contaminated clothing
• Antidotes: Special medicines called atropine and pralidoxime that reverse the poisoning
• Breathing support: Some patients need a breathing machine temporarily
• Close monitoring: Usually requires intensive care for several days

What Is the Outlook?

• With early treatment, most people recover completely
• Severe poisoning can be life-threatening
• Recovery may take several weeks
• Some patients need psychiatric support if poisoning was intentional

Prevention

If you work with pesticides:

• Always wear protective equipment (gloves, mask, protective clothing)
• Wash thoroughly after work
• Store pesticides in locked cabinets away from children
• Never put pesticides in drink bottles or food containers
• Follow all label instructions

If concerned about suicide:

• Speak to a healthcare provider
• Call a crisis helpline
• Restrict access to pesticides

When to Seek Emergency Help

Call emergency services immediately if someone has been exposed to pesticides and has:

• Difficulty breathing
• Excessive salivation or sweating
• Muscle twitching
• Confusion or drowsiness
• Very small pupils

Do not wait for symptoms to worsen - early treatment saves lives.

Resources

• UK National Poisons Information Service: TOXBASE (for healthcare professionals)
• NHS 111 (UK): For urgent medical advice
• US Poison Control: 1-800-222-1222
• World Health Organization: Pesticide Safety Resources
• Samaritans (UK crisis support): 116 123

---

References

1. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597-607. PMID: 17706760

2. King AM, Aaron CK. Organophosphate and carbamate poisoning. Emerg Med Clin North Am. 2015;33(1):133-151. PMID: 25455666

3. Jokanovic M. Neurotoxic effects of organophosphorus pesticides and possible association with neurodegenerative diseases in man: A review. Toxicology. 2018;410:125-131. PMID: 30268886

4. Eddleston M, Phillips MR. Self poisoning with pesticides. BMJ. 2004;328(7430):42-44. PMID: 14703547

5. Buckley NA, Eddleston M, Li Y, Bevan M, Robertson J. Oximes for acute organophosphate pesticide poisoning. Cochrane Database Syst Rev. 2011;(2):CD005085. PMID: 21328273

6. Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila). 2021;59(12):1282-1501. PMID: 34890230

7. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides: an intermediate syndrome. N Engl J Med. 1987;316(13):761-763. PMID: 2950322

8. Lotti M, Moretto A. Organophosphate-induced delayed polyneuropathy. Toxicol Rev. 2005;24(1):37-49. PMID: 16042503

9. Mew EJ, Padmanathan P, Konradsen F, et al. The global burden of fatal self-poisoning with pesticides 2006-15: Systematic review. J Affect Disord. 2017;219:93-104. PMID: 28531646

10. Bertolote JM, Fleischmann A, Eddleston M, Gunnell D. Deaths from pesticide poisoning: a global response. Br J Psychiatry. 2006;189:201-203. PMID: 16946353

11. Worek F, Thiermann H, Szinicz L, Eyer P. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem Pharmacol. 2004;68(11):2237-2248. PMID: 15498514

12. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev. 2003;22(3):165-190. PMID: 15181665

13. Eddleston M, Eyer P, Worek F, et al. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet. 2005;366(9495):1452-1459. PMID: 16243090

14. Gunnell D, Eddleston M, Phillips MR, Konradsen F. The global distribution of fatal pesticide self-poisoning: systematic review. BMC Public Health. 2007;7:357. PMID: 18154668

15. Eddleston M, Buckley NA, Checketts H, et al. Speed of initial atropinisation in significant organophosphorus pesticide poisoning--a systematic comparison of recommended regimens. J Toxicol Clin Toxicol. 2004;42(6):865-875. PMID: 15533024

16. Eddleston M, Mohamed F, Davies JO, et al. Respiratory failure in acute organophosphorus pesticide self-poisoning. QJM. 2006;99(8):513-522. PMID: 16861721

17. Dawson AH, Eddleston M, Senarathna L, et al. Acute human lethal toxicity of agricultural pesticides: a prospective cohort study. PLoS Med. 2010;7(10):e1000357. PMID: 21048990

18. Okumura T, Takasu N, Ishimatsu S, et al. Report on 640 victims of the Tokyo subway sarin attack. Ann Emerg Med. 1996;28(2):129-135. PMID: 8759575

19. De Bleecker J, Van Den Neucker K, Colardyn F. Intermediate syndrome in organophosphorus poisoning: a prospective study. Crit Care Med. 1993;21(11):1706-1711. PMID: 8222690

20. Karki P, Ansari JA, Bhandary S, Koirala S. Cardiac and electrocardiographical manifestations of acute organophosphate poisoning. Singapore Med J. 2004;45(8):385-389. PMID: 15284933

21. Richardson RJ, Fink JK, Glynn P, et al. Neuropathy target esterase (NTE): overview and future. Chem Biol Interact. 2013;203(1):238-244. PMID: 23085197

22. Peter JV, Sudarsan TI, Moran JL. Clinical features of organophosphate poisoning: A review of different classification systems and approaches. Indian J Crit Care Med. 2014;18(11):735-745. PMID: 25425841

---

Last Updated: 2026-01-08
Next Review: 2027-01-08
Evidence Level: High (Multiple RCTs, systematic reviews, international guidelines)

---